Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2001 Jun;60(6):592–598. doi: 10.1136/ard.60.6.592

European multicentre study to define disease activity criteria for systemic sclerosis.* II. Identification of disease activity variables and development of preliminary activity indexes

G Valentini 1, R Della 1, S Bombardieri 1, W Bencivelli 1, A Silman 1, S D'Angelo 1, M Cerinic 1, J Belch 1, C Black 1, P Bruhlmann 1, L Czirjak 1, A De Luca 1, A Drosos 1, C Ferri 1, A Gabrielli 1, R Giacomelli 1, G Hayem 1, M Inanc 1, N McHugh 1, H Nielsen 1, M Rosada 1, R Scorza 1, J Stork 1, A Sysa 1, F H J van den Hoogen 1, P Vlachoyiannopoulo 1
PMCID: PMC1753669  PMID: 11350848

Abstract

OBJECTIVE—To develop criteria for disease activity in systemic sclerosis (SSc) that are valid, reliable, and easy to use.
METHODS—Investigators from 19 European centres completed a standardised clinical chart for a consecutive number of patients with SSc. Three protocol management members blindly evaluated each chart and assigned a disease activity score on a semiquantitative scale of 0-10. Two of them, in addition, gave a blinded, qualitative evaluation of disease activity ("inactive to moderately active" or "active to very active" disease). Both these evaluations were found to be reliable. A final disease activity score and qualitative evaluation of disease activity were arrived at by consensus for each patient; the former represented the gold standard for subsequent analyses. The correlations between individual items in the chart and this gold standard were then analysed.
RESULTS—A total of 290 patients with SSc (117 with diffuse SSc (dSSc) and 173 with limited SSc (lSSc)) were enrolled in the study. The items (including Δ-factors—that is, worsening according to the patient report) that were found to correlate with the gold standard on multiple regression were used to construct three separate 10-point indices of disease activity: (a) Δ-cardiopulmonary (4.0), Δ-skin (3.0), Δ-vascular (2.0), and Δ-articular/muscular (1.0) for patients with dSSc; (b) Δ-skin (2.5), erythrocyte sedimentation rate (ESR) >30 mm/1st h (2.5), Δ-cardiopulmonary (1.5), Δ-vascular (1.0), arthritis (1.0), hypocomplementaemia (1.0), and scleredema (0.5) for lSSc; (c) Δ-cardiopulmonary (2.0), Δ-skin (2.0), ESR >30 mm/1st h (1.5), total skin score >20 (1.0), hypocomplementaemia (1.0), scleredema (0.5), digital necrosis (0.5), Δ-vascular (0.5), arthritis (0.5), TLCO <80% (0.5) for all patients with SSc. The three indexes were validated by the jackknife technique. Finally, receiver operating characteristic curves were constructed in order to define the value of the index with the best discriminant capacity for "active to very active" patients.
CONCLUSIONS—Three feasible, reliable, and valid preliminary indices to define disease activity in SSc were constructed.



Full Text

The Full Text of this article is available as a PDF (150.1 KB).

Figure 1  .

Figure 1  

Open in a new tab

Receiver operating characteristic curves showing the relation between the value of the calculated activity index and the presence of active or very active disease in (A) SSc whole series; (B) dSSc; (C) lSSc. AUC = area under the curve.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Belch J. J., Hickman P. Leukocyte activation and toxic oxygen metabolites/free radicals. Adv Exp Med Biol. 1997;428:1–5. doi: 10.1007/978-1-4615-5399-1_1. [DOI] [PubMed] [Google Scholar]
  2. Benbassat C., Schlesinger M., Luderschmidt C., Valentini G., Tirri G., Shoenfeld Y. The complement system and systemic sclerosis. Immunol Res. 1993;12(3):312–316. doi: 10.1007/BF02918260. [DOI] [PubMed] [Google Scholar]
  3. Black C. M., McWhirter A., Harrison N. K., Kirk J. M., Laurent G. J. Serum type III procollagen peptide concentrations in systemic sclerosis and Raynaud's phenomenon: relationship to disease activity and duration. Br J Rheumatol. 1989 Apr;28(2):98–103. doi: 10.1093/rheumatology/28.2.98. [DOI] [PubMed] [Google Scholar]
  4. Boers M., Tugwell P. OMERACT conference questionnaire results. OMERACT Committee. J Rheumatol. 1993 Mar;20(3):552–554. [PubMed] [Google Scholar]
  5. Brennan P., Silman A. Statistical methods for assessing observer variability in clinical measures. BMJ. 1992 Jun 6;304(6840):1491–1494. doi: 10.1136/bmj.304.6840.1491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Casas J. A., Subauste C. P., Alarcón G. S. A new promising treatment in systemic sclerosis: 5-fluorouracil. Ann Rheum Dis. 1987 Oct;46(10):763–767. doi: 10.1136/ard.46.10.763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Degiannis D., Seibold J. R., Czarnecki M., Raskova J., Raska K., Jr Soluble interleukin-2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations. Arthritis Rheum. 1990 Mar;33(3):375–380. doi: 10.1002/art.1780330310. [DOI] [PubMed] [Google Scholar]
  8. Felson D. T., Anderson J. J., Boers M., Bombardier C., Chernoff M., Fried B., Furst D., Goldsmith C., Kieszak S., Lightfoot R. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993 Jun;36(6):729–740. doi: 10.1002/art.1780360601. [DOI] [PubMed] [Google Scholar]
  9. Felson D. T., Anderson J. J. Methodological and statistical approaches to criteria development in rheumatic diseases. Baillieres Clin Rheumatol. 1995 May;9(2):253–266. doi: 10.1016/s0950-3579(05)80189-x. [DOI] [PubMed] [Google Scholar]
  10. Fiocco U., Rosada M., Cozzi L., Ortolani C., De Silvestro G., Ruffatti A., Cozzi E., Gallo C., Todesco S. Early phenotypic activation of circulating helper memory T cells in scleroderma: correlation with disease activity. Ann Rheum Dis. 1993 Apr;52(4):272–277. doi: 10.1136/ard.52.4.272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fries J. F., Hochberg M. C., Medsger T. A., Jr, Hunder G. G., Bombardier C. Criteria for rheumatic disease. Different types and different functions. The American College of Rheumatology Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1994 Apr;37(4):454–462. doi: 10.1002/art.1780370403. [DOI] [PubMed] [Google Scholar]
  12. Giordano M., Valentini G., Migliaresi S., Picillo U., Vatti M. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol. 1986 Oct;13(5):911–916. [PubMed] [Google Scholar]
  13. Gruschwitz M. S., Hornstein O. P., von Den Driesch P. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum. 1995 Feb;38(2):184–189. doi: 10.1002/art.1780380206. [DOI] [PubMed] [Google Scholar]
  14. Hughes P., Gelsthorpe K., Doughty R. W., Rowell N. R., Rosenthal F. D., Sneddon I. B. The association of HLA-B8 with visceral disease in systemic sclerosis. Clin Exp Immunol. 1978 Mar;31(3):351–356. [PMC free article] [PubMed] [Google Scholar]
  15. Kahaleh M. B., Sultany G. L., Smith E. A., Huffstutter J. E., Loadholt C. B., LeRoy E. C. A modified scleroderma skin scoring method. Clin Exp Rheumatol. 1986 Oct-Dec;4(4):367–369. [PubMed] [Google Scholar]
  16. LeRoy E. C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger T. A., Jr, Rowell N., Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988 Feb;15(2):202–205. [PubMed] [Google Scholar]
  17. LeRoy E. C. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am. 1996 Nov;22(4):675–694. doi: 10.1016/s0889-857x(05)70295-7. [DOI] [PubMed] [Google Scholar]
  18. Levesque H., Baudot N., Delpech B., Vayssairat M., Gancel A., Lauret P., Courtois H. Clinical correlations and prognosis based on hyaluronic acid serum levels in patients with progressive systemic sclerosis. Br J Dermatol. 1991 May;124(5):423–428. doi: 10.1111/j.1365-2133.1991.tb00619.x. [DOI] [PubMed] [Google Scholar]
  19. Liang M. H., Socher S. A., Roberts W. N., Esdaile J. M. Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum. 1988 Jul;31(7):817–825. doi: 10.1002/art.1780310701. [DOI] [PubMed] [Google Scholar]
  20. Medsger T. A., Jr, Silman A. J., Steen V. D., Black C. M., Akesson A., Bacon P. A., Harris C. A., Jablonska S., Jayson M. I., Jimenez S. A. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol. 1999 Oct;26(10):2159–2167. [PubMed] [Google Scholar]
  21. Patrick M. R., Kirkham B. W., Graham M., Harrision L. C. Circulating interleukin 1 beta and soluble interleukin 2 receptor: evaluation as markers of disease activity in scleroderma. J Rheumatol. 1995 Apr;22(4):654–658. [PubMed] [Google Scholar]
  22. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980 May;23(5):581–590. doi: 10.1002/art.1780230510. [DOI] [PubMed] [Google Scholar]
  23. Scott D. L., Panayi G. S., van Riel P. L., Smolen J., van de Putte L. B. Disease activity in rheumatoid arthritis: preliminary report of the Consensus Study Group of the European Workshop for Rheumatology Research. Clin Exp Rheumatol. 1992 Sep-Oct;10(5):521–525. [PubMed] [Google Scholar]
  24. Seibold J. R., Medsger T. A., Jr, Winkelstein A., Kelly R. H., Rodnan G. P. Immune complexes in progressive systemic sclerosis (scleroderma). Arthritis Rheum. 1982 Oct;25(10):1167–1173. doi: 10.1002/art.1780251004. [DOI] [PubMed] [Google Scholar]
  25. Symmons D. P. Disease assessment indices: activity, damage and severity. Baillieres Clin Rheumatol. 1995 May;9(2):267–285. doi: 10.1016/s0950-3579(05)80190-6. [DOI] [PubMed] [Google Scholar]
  26. Vitali C., Bencivelli W., Isenberg D. A., Smolen J. S., Snaith M. L., Sciuto M., Neri R., Bombardieri S. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol. 1992 Sep-Oct;10(5):541–547. [PubMed] [Google Scholar]
  27. van den Hoogen F. H., Boerbooms A. M., Swaak A. J., Rasker J. J., van Lier H. J., van de Putte L. B. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 1996 Apr;35(4):364–372. doi: 10.1093/rheumatology/35.4.364. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES